Could this approach work
with dystrophin exon skipping?
Not exact matches
Children
with muscular dystrophy lack the gene required to regulate
dystrophin, a protein for muscle growth and stability.
Duchenne muscular dystrophy is caused by problems
with the body's ability to produce
dystrophin, a long protein chain that binds the interior of a muscle fiber to its surrounding support structure.
In the study, researchers worked
with a mouse model that has a debilitating mutation on one of the exons of the
dystrophin gene.
Bottom row: skeletal muscle
with restored
dystrophin after application of the CRISPR / Cas9 platform.
They had been working
with a worm model of Duchenne muscular dystrophy, a severe form of the disease that strikes young boys and is caused by mutations in the gene that encodes the
dystrophin protein.
Duchenne typically occurs through one mutation in a gene called
dystrophin, which makes a protein
with the same name.
Mice treated
with antisense RNA (bottom) produced more
dystrophin — colored red in this image — than did control mice (top).
Experiments have shown treatment
with sildenafil significantly improved heart function in mice missing the
dystrophin protein.
Their study published online ahead of print in PNAS Early Edition suggests a new therapeutic strategy for patients
with Duchene muscular dystrophy, a progressive neuromuscular condition, caused by a lack of
dystrophin, that usually leaves patients unable to walk on their own by age 10 - 15.
The study authors previously found out that NF - κB is active in
dystrophin - deficient muscle years before the onset of symptoms, suggesting that very early treatment of Duchenne Muscular Dystrophy patients
with VBP15 may prevent or delay the onset of some clinical symptoms.
Children
with DMD have a mutation that cripples the body's ability to produce a protein called
dystrophin, which helps absorb the shock or energy that's created when a muscle contracts.
Using the natural human development process as a guide, the researchers developed ways to mature muscle cells in the laboratory to create muscle fibers that restore
dystrophin, the protein that is missing in the muscles of boys
with Duchenne.
The study is the first to show that damaged
dystrophin underlies both genetic and acquired cardiomyopathy, says Jeffrey A. Towbin, a cardiologist
with the Baylor College of Medicine and Texas Children's Hospital in Houston.
When they killed the animals a week later, they found that the virus had broken apart
dystrophin in their hearts and that the membranes of heart cells infected
with Coxsackie B virus were more permeable to blue dye than uninfected cells.
Muscles from mice treated
with modified human stem cells show human
dystrophin - producing muscle fibers (yellow) integrated among mouse muscle fibers (red).
After cultured rat heart cells were infected
with the Coxsackie B virus, the amount of normal
dystrophin declined within 3 days.
The team previously found that NF - κB is active in
dystrophin - deficient muscle years before the onset of symptoms, suggesting that very early treatment of Duchenne muscular dystrophy patients
with VBP15 may prevent or delay the onset of some clinical symptoms.
Lead investigators David Burns and Ken O'Halloran at University College Cork, in conjunction
with collaborator labs at the University of Calgary and Trinity College Dublin, performed experiments in mice lacking
dystrophin, the muscle protein that malfunctions in DMD.
In the absence of
dystrophin, the polarity effector Par1b is dysregulated, leading to the failure of Par3 to become localized to the cortex associated
with the basal lamina.
Patients
with DMD lack
dystrophin, a protein that gives muscle cells structure.
In a subsequent study, they used CRISPR
with two gRNAs to delete exon 51 or exons 45 - 55 in patient myoblasts; when injected into DMD mice, these cells expressed functional
dystrophin.
People
with DMD do not make
dystrophin, a protein that helps keep the muscles intact.
First, CRISPR would need to be delivered to both cardiac and skeletal muscle cells, where precision editing of the
dystrophin gene would take place,
with minimal risk of off - target editing.
In accordance
with this result, Nelson et al. find that
dystrophin restoration is maintained for at least six months.
They also described the gene's size and genetic deletions associated
with disease, including a very large deletion of the gene coding for
dystrophin found in a patient
with mild disease.